Exact Sciences' shares pop on positive Cologuard trial results

Exact Sciences' shares pop on positive Cologuard trial resultsПодробнее

Barry Berger Discusses CologuardПодробнее

Shares of Exact Sciences Corp. Tumble Following Results from Colon Cancer Detection TestПодробнее

Exact Sciences CEO on the Cologuard maker's surge in revenue and usersПодробнее

Comparison of Cologuard With Other CRC Screening ToolsПодробнее

Exact Sciences CEO explains new cancer screening testПодробнее

How to properly use Cologuard colon cancer at-home test kitПодробнее

Exact Sciences CEO: $2.8 billion Genomic Health deal can yield $1.6 billion in revenueПодробнее

Exact Sciences - Oncotype MAP™ Pan-Cancer Tissue TestПодробнее

Exact Sciences - Multi-Cancer Earlier DetectionПодробнее

At-home Colon Cancer Test Can Save a Life – If You Follow Up | Sanford Health NewsПодробнее

Exact Sciences CEO: Life Changing Stock | Mad Money | CNBCПодробнее

Case Study: Exact SciencesПодробнее

SABCS 2022 - Exact Sciences Announces Data Supporting Future of Breast Cancer Care ContinuumПодробнее

Exact Sciences developing new cancer tests at Madison facilityПодробнее

Barry Berger on the Significance of the Cologuard Screening TestПодробнее

Exact Sciences 2013 OverviewПодробнее

Editorial: Exact Sciences is detecting cancer, building communityПодробнее

10 Years of Impact with Cologuard® and Exact SciencesПодробнее

New non-invasive option for colon cancer screeningПодробнее